These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2758 related articles for article (PubMed ID: 32903482)

  • 21. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
    Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
    Front Immunol; 2021; 12():732135. PubMed ID: 34925314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR-NK Cells in the Treatment of Solid Tumors.
    Wrona E; Borowiec M; Potemski P
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
    Schmidt P; Raftery MJ; Pecher G
    Front Immunol; 2020; 11():611163. PubMed ID: 33488617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
    Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.
    Lu SJ; Feng Q
    Stem Cells Transl Med; 2021 Nov; 10 Suppl 2(Suppl 2):S10-S17. PubMed ID: 34724715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.
    Daher M; Rezvani K
    Curr Opin Immunol; 2018 Apr; 51():146-153. PubMed ID: 29605760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in manufacturing chimeric antigen receptor immune cell therapies.
    Ramamurthy A; Tommasi A; Saha K
    Semin Immunopathol; 2024 Aug; 46(5):12. PubMed ID: 39150566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
    Liu J; Zhou G; Zhang L; Zhao Q
    Front Immunol; 2019; 10():456. PubMed ID: 30941126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reprogramming natural killer cells for cancer therapy.
    Wang K; Wang L; Wang Y; Xiao L; Wei J; Hu Y; Wang D; Huang H
    Mol Ther; 2024 Sep; 32(9):2835-2855. PubMed ID: 38273655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR-expressing NK cells for cancer therapy: a new hope.
    Xia J; Minamino S; Kuwabara K
    Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 138.